Pasireotide diaspartate
Modify Date: 2024-01-09 12:07:58
Pasireotide diaspartate structure
|
Common Name | Pasireotide diaspartate | ||
|---|---|---|---|---|
| CAS Number | 820232-50-6 | Molecular Weight | 1313.412 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C66H80N12O17 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Pasireotide diaspartatePasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. |
| Name | Pasireotide diaspartate |
|---|---|
| Synonym | More Synonyms |
| Molecular Formula | C66H80N12O17 |
|---|---|
| Molecular Weight | 1313.412 |
| Exact Mass | 1312.576416 |
| I4P76SY3N4 |
| L-Aspartic acid, compd. with cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl] (2:1) |
| pasireotide aspartate |
| Pasireotide diaspartate |
| L-Aspartic acid - cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-benzyl-L-tyrosyl-L-phenylalanyl-(4R)-4-{[(2-aminoethyl)carbamoyl]oxy}-L-prolyl] (2:1) |
| Signifor |